Chen Zhicong, He Anbang, Liu Yuchen, Huang Weiren, Cai Zhiming
Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518039 Guangdong Province, People's Republic of China.
Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Centre, Beijing, 100034, China.
Synth Syst Biotechnol. 2016 Sep 14;1(4):216-220. doi: 10.1016/j.synbio.2016.08.001. eCollection 2016 Dec.
Synthetic biology is an emerging field focusing on engineering genetic devices and biomolecular systems for a variety of applications from basic biology to biotechnology and medicine. Thanks to the tremendous advances in genomics and the chemical synthesis of DNA in the past decade, scientists are now able to engineer genetic devices and circuits for cancer research and intervention, which offer promising therapeutic strategies for cancer treatment. In this article, we provide a systemic review on recent development achieved by the synthetic biologists, oncologists and clinicians of one National "973" Plan. We expand the synthetic biology toolkits involving DNA, RNA and protein bio-parts to explore various issues in cancer research, such as elucidation of mechanisms and pathways, creation of new diagnostic tools and invention of novel therapeutic approaches. We claimed that the Chinese synthetic biologists are promoting the basic research productions of tumor synthetic biology into the clinic.
合成生物学是一个新兴领域，专注于设计遗传装置和生物分子系统，以用于从基础生物学到生物技术及医学等各种应用。得益于过去十年基因组学和DNA化学合成方面的巨大进展，科学家如今能够设计用于癌症研究和干预的遗传装置和电路，为癌症治疗提供了有前景的治疗策略。在本文中，我们对一项国家“973”计划中合成生物学家、肿瘤学家和临床医生所取得的近期进展进行了系统综述。我们扩展了涉及DNA、RNA和蛋白质生物部件的合成生物学工具包，以探索癌症研究中的各种问题，如机制和途径的阐明、新诊断工具的创建以及新型治疗方法的发明。我们宣称中国的合成生物学家正在推动肿瘤合成生物学的基础研究成果走向临床。
